One huge market. Six horses in the race (so far). Lots of prize money to go around.
One huge market. Six horses in the race (so far). Lots of prize money to go around.
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
Red Light Holland acquires a Netherlands distributor of psilocybin-based products.
MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.
Psychedelic drug stocks represent (by far) the best new opportunity in life sciences today. Institutional capital is flooding into the sector. But market analysts are asleep-at-the-wheel here.
Cybin announces two new drug candidates for its R&D pipeline as its pre-clinical research deepens.
Field Trip closes on a CAD$95 million bought deal financing, nearly double the original CAD$50 million offering.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now